- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02421497
MRI Technical Development and Applications in Kidney Disease
Magnetic resonance imaging (MRI), as a non-invasive and non-contrast enhanced technique, has the potential to improve patient health care and management. The overall objective of proposed project is to:
- develop, customize, and optimize anatomic and functional MRI methods,
- explore the use of MRI methods to study CKD and evaluate post-transplant kidneys, and
- investigate the potential of MRI in the diagnosis, prognosis, and monitoring of the progression of renal dysfunction.
In addition to direct studies of the kidney, brain MRI studies will also be performed to identify the cerebrovascular and cognitive effects of chronic renal function deficiency and medical treatment (e.g. hemodialysis and immunosuppression). The brain and kidneys have similar vascular bed, and both are susceptible to vascular injury, which provides the pathological basis for the widely recognized association of reduced renal function with prevalent cerebrovascular diseases (CVDs) and cognitive impairment (CI). The MRI methods in the brain will be applied to explore the origins for widely observed CVDs and prevalent cognitive impairment (CI) in kidney disease patients.
Study Overview
Status
Detailed Description
Specific Aims
The overall objective is to develop and validate MRI methods for the evaluation and monitoring of renal status and associated cerebrovascular effects of renal dysfunction and treatment. The proposed project include two phases: 1) MRI technical development and validation with reproducibility studies; 2) clinical pilot studies with two patient populations (CKD patients and renal transplant recipients) to explore the potential of MRI in evaluating CKD, post-transplantation renal dysfunction and cerebrovascular pathophysiology associated with or induced by reduced kidney function and renal replacement treatment. The ultimate goal is to use MRI as a non-invasive and non-contrast enhanced tool to facilitate the diagnosis and prognosis of renal dysfunction and associated diseases, and to assess the efficacy of therapeutic interventions, and monitor disease progress across time.
Specific Aim 1: Imaging technical development and protocol optimization for renal and cerebral MRI.
The overall goal is to develop, customize and optimize new MRI methods to overcome challenges due to physiological motions and facilitate clinical research studies of renal and cerebral diseases, which will include but not are limited to the following aspects.
Sub-Aim 1.1: Develop imaging methods to improve MRI quality and efficiency for renal disease studies.
Sub-Aim 1.2: Optimize gas-challenge functional MRI protocols to study cerebral and renal vascular endothelial dysfunction.
Sub-Aim 1.3: Evaluate the reproducibility of cerebral and renal MRI methods.
Specific Aim 2: Perform pilot studies to evaluate the potential of MRI in CKD patients and renal transplant recipients.
Sub-Aim 2.1: Evaluate the correspondence of MRI measures with clinical metrics (i.e. eGFR) and routinely assessed cognitive functions from CKD and ESRD patients.
This will be accomplished by performing both cross-sectional and longitudinal studies, which will allow us to evaluate the diagnostic and prognostic potential of these non-invasive imaging methods. The investigators hypothesize that the measurements from cerebral and/or renal MRI can effectively reflect cerebral and/or renal (anatomic and physiological) changes induced by CKD or dialysis treatment.
Sub-Aim 2.2: Investigate the potential of MRI methods in the evaluation of post-transplant kidneys.
This will be accomplished by imaging transplant recipients in three distinct cohorts; those with good allograft function but coming in for routine protocol biopsy, with stable renal function, and with unstable renal function due to post-transplant complications. These patient populations will receive protocol biopsies (i.e. scheduled repeat biopsies) as standard of care; therefore pathologic results will be available for correlation with MRI measures. The investigators hypothesize that MRI methods can be a non-invasive surrogate marker of renal tissue properties and functional changes induced by renal post-transplant dysfunction (e.g. renal rejection) currently only obtained through biopsy.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Xiufeng Li, Ph.D.
- Phone Number: 612-625-7872
- Email: lixx1607@umn.edu
Study Contact Backup
- Name: Michelle Hartwig
- Phone Number: 612-626-0021
- Email: mhartwig@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- Center for Magnetic Resonance Research
-
Contact:
- Xiufeng Li, Ph.D.
- Phone Number: 612-626-2001
-
Principal Investigator:
- Xiufeng Li, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
For Specific Aim 1: MRI Technical Development Studies
Inclusion Criteria:
1. Healthy Volunteer
Exclusion Criteria:
- Ferromagnetic implants
- Any foreign metal objects in the body
- History of shrapnel or shot gun injury
- Cardiac pacemakers
- Defibrillator
- Neuronal stimulator
- Magnetic aneurysm clip
- Large tattoos on the abdomen or the brain and neck
- Hip replacement
- Too large to fit in the magnet (body mass index >= 40, approx.)
- Severe claustrophobia
- Women with pregnancy
For Specific Aim 2: Pilot Studies with Patients
Studies for CKD
Inclusion
- English- speaking as primary language.
- Age 45 years and older
- Able to complete an approximately 90 minute cognitive testing battery.
- Able to sign the informed consent, or allow a caregiver, relative, surrogate, or witness to sign the informed consent if participant is unable to do so.
- GFR < 90 ml/min/1.73m2
Exclusion
- Acute psychiatric illness that would impede cognitive testing
- Active chemical dependence, such as alcohol, narcotics or other drugs
- Legally blind or unable to complete cognitive tests due to visual loss or deafness
- Dialysis dependent or renal transplant recipient at time of screening or baseline
- Chronic obstructive pulmonary disease
- Severe CI unable to complete the Modified Mini-Mental State Examination [3MSE]
Studies for Renal Transplantation
Inclusion
- Able to sign the informed consent, or allow a caregiver, relative, surrogate, or witness to sign the informed consent if participant is unable to do so.
- Age 45 years and older
Exclusion
- Not on dialysis due to allograft failure
- Chronic obstructive pulmonary disease
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Normal Healthy Volunteer
|
Non-CKD Control
|
Chronic Kidney Disease (CKD)
|
Dialysis Patients
|
Renal Transplant Recipients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correspondence of MRI measures with clinical metrics (i.e. eGFR) and routinely assessed cognitive functions from CKD and ESRD patients.
Time Frame: up to three years
|
MRI measures will be evaluated both globally and regionally (e.g.
frontal lobe and the hippocampus of the brain, renal cortex and medulla in each and both kidneys).
The correlations among MRI measurements, the degree of CKD disease (as evaluated by eGFR) and the severity of cognitive impairment will be assessed using both cross-sectional and longitudinal analyses.
Non-parametric analysis approach will be used instead of parametric if appropriate.
|
up to three years
|
The potential of MRI methods in the evaluation of post-transplant kidneys.
Time Frame: Up to three years
|
For each region in kidneys (renal cortex and medulla), each MRI measurement from the cross-sectional studies of transplant recipients with stable renal functional will be correlated to the levels of transplant kidney function (e.g. eGFR). Imaging results from transplant recipients with unstable renal function will be compared between patients with and without diagnosed acute rejection, and before and after the acute rejection treatment for patients with positive response. Note: For both outcomes, multi-parametric MRI measurements will be used in the evaluation, including but not limited to MRI relaxation times, blood flow and diffusion. |
Up to three years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Xiufeng Li, Ph.D., Univesity of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1410M54981
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina